logo-loader
viewVentriPoint Diagnostics Ltd.

Ventripoint Diagnostics shares pump after positive findings from sarcoidosis study in Netherlands using VMS

Pulmonary hypertension occurs in 6% to 74% of patients with sarcoidosis ...

1546868762_Heart.jpg
Cardiac specialists at the hospital in the Netherlands are using the med-tech group's VMS system

Ventripoint Diagnostics Ltd (CVE:VPT) (OTCMKTS:VPTDF) revealed its VMS heart monitoring system was again proving its worth - after positive results from the St Antonius Hospital in the Netherlands, sending shares in the company higher.

Cardiac specialists there are using the med-tech group's VMS system to study patients with sarcoidosis, an inflammatory disease, which affects multiple organs in the body, including the heart.

READ: Ventripoint says Johns Hopkins doctor cited VMS+ heart analysis system’s clinical feasibility at Milan conference

The cause of Sarcoidosis is unknown and affects about 50,000 people a year in the US. Between 150,000 and 200,000 people have chronic sarcoidosis.

Pulmonary hypertension occurs in 6% to 74% of patients with sarcoidosis. This is a serious complication leading to early death.

Around 500 sarcoidosis patients have been studied at the Dutch hospital so far. The focus is on the early detection of pulmonary hypertension.

The study has found almost 20 patients with confirmed pulmonary hypertension and the cardiac team will continue to monitor the right-ventricular function of these patients, using the Ventripoint solution, to better understand the progress of the disease.

"The right heart is difficult to assess, and in patients with pulmonary disease, this challenge is even more difficult," said Dr Marloes Huitema, MD Cardiology at St. Antonius Hospital.

"Ventripoint provides a solution that allows us to overcome these barriers and might be an alternative to MRI, which is costly, time consuming and not possible for all patients.

"Furthermore, in those patients with pulmonary hypertension, the Ventripoint technology gives us an ability to repeatedly evaluate the right-ventricular dimensions with a rapid, inexpensive, non-invasive procedure to determine therapeutic efficacy."

Ventripoint noted that there were many potential applications for its VMS technology; providing confidence in the volumetric measurements of patients with accuracy comparable to cardiac MRI (magnetic resource imaging) is its strength.

The group's VMS Plus heart monitoring technology measures whole heart function using conventional ultrasound.

The company has developed a suite of applications for all major heart diseases and wants to commercialize the technology to improve heart care.

Shares in Toronto added almost 12% to $0.19.

Contact Giles at [email protected]

Follow him on Twitter @ Gile74

Quick facts: VentriPoint Diagnostics Ltd.

Price: 0.075 CAD

TSX-V:VPT
Market: TSX-V
Market Cap: $5.23 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VentriPoint Diagnostics Ltd. named herein, including the promotion by the Company of VentriPoint Diagnostics Ltd. in any Content on the Site,...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Ventripoint Diagnostic focussing on sales in 2020 as they...

Ventripoint Diagnostics (CVE:VPT-OTCQB: VPTDF) Executive Chairman and Acting CEO Dr George Adams sat down with Steve Darling from Proactive in Vancouver with news the company has 11 purchase orders in for their echocardiogram system that provides cardiac measurements. Adams telling Proactive...

on 20/2/20

2 min read